Cowen Healthcare Conference Bill Sibold, Global Franchise Head Multiple Sclerosis, Oncology & Immunology, Sanofi Genzyme

Boston – March 7, 2017 Forward Looking Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

2 Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

3 2016 Financial Performance Stronger than Initial Expectations

Company Sales(1) Business EPS(2)

€34,060m €33,821m(3) €5.68 €5.64 +1.2% +4.1% at CER(4,5) at CER(4,5)

FY 2015 FY 2016 FY 2015 FY 2016

(1) FY 2015 Company Sales restated to exclude Animal Health Business (2) FY 2015 and FY 2016 Business EPS includes the contribution from Animal Health (3) FY 2016 Company Sales were €36,529m (+1.8% at CER) including Animal Health (previously referred to as “Aggregate Sales”) (4) Evolution at Constant Exchange Rates (CER) 4 (5) On a reported basis, FY 2016 sales were down -0.7% and Business EPS was up +0.7% 2016 Sales Increase Driven by Double-Digit Growth at Sanofi Genzyme

2016 Sales by Global Business Unit Growth at CER Company Sales €33,821m +1.2%

(1) Sanofi Genzyme (Specialty Care) €5,019m +17.3%

(2) Sanofi Pasteur (Vaccines) €4,577m +8.8%

(1) Diabetes & Cardiovascular €6,397m -2.0%

(3,4,5) General Medicines & Emerging Markets €14,498m -3.3%

(6) Consumer Healthcare €3,330m -1.6%

(1) Does not include Emerging Markets sales Eastern Europe (except Eurasia), Japan, South Korea, (2) Reflecting reclassification of VaxServe from Sales to Other Australia, New Zealand and Puerto Rico revenues from Jan 1, 2016 (5) Excluding global Consumer Healthcare sales (3) Includes Emerging Markets sales for Diabetes & (6) Consumer Healthcare expected to become a GBU in 2017 and Cardiovascular and Specialty Care includes sales in Emerging Markets 5 (4) Emerging Markets: World excluding U.S., Canada, Western & Pictures by Freepik Rare Disease and Multiple Sclerosis Driving Growth in Specialty Care

Global Specialty Care ● Speciality Care franchises represent Franchise Sales around 18% of Sanofi sales(1) €5,950m ● Proven ability to execute in €5,168m €2,777m specialized disease areas +11.7% at CER ● Leading position in Rare Diseases

€2,550m +17.2% ● Rapidly growing Multiple Sclerosis franchise at CER €1,720m ● Re-building a competitive position in Oncology €1,114m +56.1% at CER ● New Sanofi Genzyme Immunology €1,453m €1,504m franchise -2.2% at CER

● Dupixent® and Kevzara® U.S. launch 2015 2016 preparation activities ongoing(2) Rare Diseases Multiple Sclerosis Oncology

(1) Calculated using FY 2016 sales (2) Dupixent® and Kevzara® are investigational agents under clinical development and their safety and 6 efficacy have not been fully evaluated by any Regulatory Authority except in Canada for Kevzara® Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

7 Rare Diseases: Strong New Patient Accrual and Emerging Markets Growth Sustained in 2016

Rare Diseases Sales ● Gaucher franchise grew +9.6% to €854m ● Promote use of proven screening €2,777m +11.7% at CER protocols among hematologists €2,550m ● Optimize launch of Cerdelga®

● EM sales up +27.1% to €239m €2,137m ● Fabry franchise grew +14.7% to €674m ● Focus primarily on nephrologists and family tree mapping to drive patient identification ● EM sales up +25.4% to €68m & ● Pompe franchise grew +13.5% to €725m ● Drive testing of high risk patients in neurology and neuromuscular specialty areas Other ● EM sales up +20.2% to €102m

2014 2015 2016

8 Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

9 Multiple Sclerosis Franchise Continued to Deliver Strong Growth in 2016

Multiple Sclerosis Sales

€1,720m +56.1% at CER

€425m ● Fastest growing oral relapsing MS +79.0% (1) at CER product with sales up +49.7% in 2016 ● Number 1 switched to DMT in the U.S.(2) €1,114m

€1,295m ● Increasing breadth and depth of +49.7% prescribing with sales up +79.0% at CER €467m in 2016

2014 2015 2016

DMT: Disease Modifying Therapy (1) Sanofi Genzyme market research (2) IMS NPA Market Dynamics 10 Attractive Efficacy, Safety, Tolerability and Once-Daily Oral Dosing Profile(1)

● Approved in more than 70 countries with ~67,000 patients currently treated worldwide ● Growing and positive experience among patients and neurologists(2) ● Established safety and tolerability with over 10 years of clinical trial data(3) ● Only oral RMS treatment to: ● Significantly reduce the risk of disability progression in two Phase III studies(4) ● Studied in newly diagnosed RMS patients, 72% of whom remained relapse free(5)

RMS: relapsing multiple sclerosis (1) AUBAGIO® (teriflunomide) is effective across key measures of disease activity: sustained disability progression (14 mg only), annualized relapse rate, and MRI activity. Common side effects with AUBAGIO led to treatment discontinuation rates ≤3.3% in clinical trials. (2) Sanofi Genzyme market research (3) The TEMSO Extension Study: Kappos L et al. ECTRIMS 2015. P1099, O’Connor P et al. ECTRIMS 2015. P555. (4) TEMSO study: O’Connor P et al. N Engl J Med. 2011;365:1293-1303; TOWER study: Confavreux C et al. Lancet Neurol. 2014;13:247-256. 11 (5) TOPIC study: Miller AE, et al. Lancet Neurol. 2014;13:977-986. Making Steady TRx Share Gains

Oral Therapies Have Gained Aubagio® is the Fastest Growing Significant Market Share(1) Oral Relapsing MS Product(2)

U.S. TRx Share U.S. TRx Share 100% 6% 9% 10% 10% 11% 90% 25% ® 80% Tecfidera 21.2% 70% 20% 52% 60% 60% 55% 74% 50% 86% 15% Gilenya® 11.4% 40% 10% 30%

20% 9.1% 37% 5% 30% 34% 10% 17% 7% 0% 0% 2012 2013 2014 2015 2016 Feb-15 Aug-15 Feb-16 Aug-16 Feb-17 Injectables Orals Intravenous

(1) IMS NPA/NSP, January 2017 (2) Oral category includes Aubagio®, Gilenya®, Tecfidera®, laquinimod, 2nd Gen S1Ps Intravenous category includes Tysabri®, Lemtrada®, ocrelizumab, daclizumab Injectable category includes Avonex®, Betaseron/Betaferon®, Copaxone®, Rebif®, Extavia®, Plegridy™ 12 (3) IMS NPA, week ending February 10th, 2017 Potential to Change Relapsing MS Treatment with an Established Benefit-Risk Profile(1,2)

● Approved in more than 60 countries with over 12,000 patients treated commercially worldwide ● Over 12 years of clinical trial data and 8,600 patient-years of follow up ● Only relapsing MS therapy which offers efficacy in the absence of chronic treatment(3) ● No retreatment with Lemtrada® after the initial 2 courses in the core studies for a majority of patients through Year 6(4) ● Draft ICER report finds Lemtrada® represents best long-term cost-effectiveness(5)

DMTs: Disease-Modifying Therapies and noting Lemtrada® may cause an increased risk of malignancies (1) The most common side effects of Lemtrada® are rash, headache, including thyroid cancer, melanoma and lymphoproliferative disorders. thyroid disorder, pyrexia, nasopharyngitis, nausea, urinary tract Lemtrada® is contraindicated in patients with HlV infection. infection, fatigue, insomnia, upper respiratory tract infection, herpes viral (3) Sustained improvements in relapse, disability, and MRI over 5 years in infection, urticaria, pruritus, fungal infection, arthralgia, pain in extremity, active RRMS in the absence of continuous dosing demonstrated in back pain, diarrhea, sinusitis, oropharyngeal pain, paresthesia, CARE-MS I and II extension studies dizziness, abdominal pain, flushing, and vomiting. Other serious side (4) The percentages of those not receiving retreatment with Lemtrada were: effects associated with Lemtrada® include autoimmune thyroid disease, 64% from CARE-MS I and 55% from CARE-MS II. autoimmune cytopenias, infections and pneumonitis. (5) Institute for Clinical and Economic Review (ICER) Evidence Report on (2) Label includes a boxed warning noting a risk of serious, sometimes fatal Disease-Modifying Therapies for Multiple Sclerosis, including autoimmune conditions, serious and life threatening infusion reactions daclizumab and ocrelizumab (January 2016) 13

Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

14 Growth in Rheumatoid Arthritis Market Expected to be Driven by Non-TNFα Inhibitor Class

Market Expected to Grow ~2% 2017-2022 CAGR with IL-6 Inhibitors Projected to Grow ~7%(1,2)

~$22bn ~$20bn CAGR $19bn +7% CAGR +7%

$21bn

CAGR -0.8%

2015 2017 2022 IL-6 inhibitors Others(3) Anti-TNFα

(1) DRG (G7), December 2016 (2) Forecasts include generic, branded and biosimilar products (3) Others includes DMARDs, CD-20 and T-cell agents, JAK inhibitors and others 15 Non-TNFα MOAs Now Included in RA First Line Biologic Recommendations Following DMARD Failure

2015 ACR Recommendation 2013 EULAR Recommendation

● TNFα inhibitor or non-TNFα biologic, ● TNFα inhibitor, Orencia® and Actemra® either in combination with MTX or as recommended as first line biologic in monotherapy, recommended as first line combination or as monotherapy if biologic following DMARD failure(1) MTX/DMARD are not tolerated(2) ● Rituxan® and Xeljanz® recommended following first line biologics

Use of Non-TNFα MOA Products is Increasing and is Over 50% Beyond First Line Biologics(3) (TRx Market Share)

8% 15% 51% 56% 84% 81% 84% Non-TNFα MOA 81% 49% 44% Anti-TNFα 16% 19% 1st line biologic 2nd line biologic 3rd line biologic 1st line biologic 2nd line biologic 3rd line biologic

RA: rheumatoid arthritis; MTX: Methotrexate; DMARD: Disease-Modifying (1) Based on moderate to very low evidence Anti-Rheumatic Drugs; MoA: Mechanism of Action (2) When prognostically unfavorable factors present; Under certain Rituxan® (rituximab) and Actemra® (tocilizumab) are marketed by Roche; conditions, Rituxan® is recommended as first line biologic Orencia® (abatacept) is marketed by BMS; (3) Source: IPSOS 16 Xeljanz® (tofacitinib) is marketed by Pfizer

New RA Market Trends: Anti-TNFα Cycling Declining with More Switching to Non-TNFα MOAs and Monotherapy

Other Patient Flow Biologic (% of patients) Anti-TNFα 2nd Combination Anti-TNFα Anti-TNFα Therapy Cycling ~50% (Add to MTX) Other 2nd Biologic Biologicbiologic (change MoA)

DMARD-IR (G7) New Trends ● Anti-TNFα in 1st line decreasing Anti-TNFα ● Anti-TNFα cycling declining with more evidence showing improved efficacy from ~50% switching to a non-TNFα MOA Monotherapy Other Biologicbiologic ● Increasing number of patients on monotherapy and guidelines supporting IL6 as monotherapy IL-6R ● Patient preference for SC administration

MTX – Methotrexate DMARD – Disease-Modifying Anti-Rheumatic Drugs MoA – Mechanism of Action Note: Biologics penetration varies somewhat by region Source: IPSOS data 2014 – Decision Resources 2014 17 (1) Recently Received First Approval in Canada and U.S. Launch Preparation Ongoing

● IL-6 plays key roles in the local joint symptoms and systemic manifestations of rheumatoid arthritis (RA)

● Positive Phase 3 efficacy/safety data in methotrexate-inadequate responder (IR) and difficult-to-treat TNF-IR populations(2)

● Positive Kevzara® monotherapy efficacy data ® (3) compared to Humira monotherapy ● Preferred SC administration with less frequent Q2W dosing

Expect re-submission of U.S. BLA in Q1 2017(4)

Kevzara is developed in collaboration with Regeneron Pharmaceuticals, Inc. Kevzara is an investigational agent under clinical development and its safety and efficacy has not been fully evaluated by any Regulatory Authority except in Canada (1) Brand name has been conditionally approved (2) Most frequently reported Treatment Emergent Adverse Events include serious infections, injection site erythema and neutropenia (3) Based on one head to head superiority study comparing sarilumab and Humira in improving signs and symptoms of RA in adults (MONARCH). A second confirmatory study has not been conducted. Neutropenia, which was not associated with infections, was more common with sarilumab than Humira®. Not included in the initial BLA filed with FDA; Humira® (adalimumab) is an AbbVie brand (4) Subject to successful FDA pre-license inspection related to Dupixent 18 A Pipeline in a Product - Clinical Studies in Multiple Indications Underway

Type 2, including Th-2 mediated diseases Atopic dermatitis (AD)  Phase 3, March 29 FDA PDUFA Date  Accepted for review by EMA in Dec 2016

Asthma  Phase 3 fully enrolled and U.S. submission expected in Q4 2017

Pediatric expansion in AD(1) and Asthma DUPILUMAB  Ph 3 studies in AD (age 6-11 and 12-17) and Asthma (age 6-11) expected to start in 2017

Nasal polyposis  Phase 3 started in Q4 2016

Additional Eosinophilic esophagitis  Ph 2 data exp. H2 17 Indications Food allergy  Phase 2 expected to start H2 17

(1) FDA Breakthrough designation for adults and pediatric moderate to severe atopic dermatitis 19 ® Potential First-in-Class Biologic for Adults with Uncontrolled Moderate to Severe AD

Atopic Dermatitis (AD) IGA 4 IGA 1

● Characterized by intense itching and recurrent eczematous lesions ● Multifactorial etiology involving immune-mediated inflammation, genetic factors, and environmental triggers ● Although it often starts in infancy, it is also highly prevalent in adults ● BSA affected: 86.5% ● BSA affected: 2.5% ● EASI score: 51.5 ● EASI score: 3.1 ● Pruritus NRS: 7 ● Pruritus NRS: 1.6 ● AD duration: 48 years

Pictures from Phase 3 clinical trial provided for illustration purposes only to show how the clinical parameters above may correlate to the clinical presentation of a patient.(1)

BLA accepted for priority review by the FDA with PDUFA date of March 29, 2017

Dupixent® is developed in collaboration with Regeneron Pharmaceuticals, Inc. Dupixent® is an investigational agent under clinical development and its safety and efficacy has not been fully evaluated by any Regulatory Authority IGA: Investigator Global Assessment BSA: Body Surface Area EASI: Eczema Area and Severity Index NRS: Numerical Rating Scale (1) Images are taken from one patient at baseline (left) and at 16 weeks (right). Results were not representative of all patients and individual results did vary. In phase 3 clinical trials, the percentage of patients achieving an IGA score of 0 or 1 ranged from 36%-38%. Adverse events that were higher for Dupixent® vs placebo included injection site reactions and conjunctivitis; Photo used with permission 20 AD Sufferers Often Experience Severe, Persistent Itch

Characteristics and Consequences of Itch in Moderate-to-Severe AD (N = 380 patients)(1)

Severe 61% experienced severe or unbearable itching*

reported daily itch symptoms† Frequent 86%

Long-lasting 63% reported itching at least 12 hours a day*

reported moderate or extreme Pain 77% pain or discomfort‡

nights per week, on average, were interrupted Disrupted sleep 4.4 by itching†

*Assessed using the 5-D pruritus scale.(2) †Assessed using the Patient-oriented Eczema Measure (POEM).(3) ‡Assessed using EuroQol (EQ-5D).(4)

(1) Simpson EL et al, J Am Acad Dermatol. 2016;74(3):491-498 (2) Elman S et al. Br J Dermatol. 2010;162(3):587-593. (3) Charman CR et al. Arch Dermatol. 2004;140(12):1513-1519. 21 (4) Yang Y et al. Eur J Health Econ. 2015;16:927-939. AD Treatment Guidelines Recommend Increasing Intensity of Therapy as Disease Severity Advances(1)

Current AD Treatment Algorithm(2) Potential Limitations of Currently Available Therapies

Systemic or UV therapy ● Topical corticosteroids (TCS): + Mid-high potency TCS/TCI Current standard of care, can be effective, + Basic treatment (3)

severe but not recommended for prolonged use Mid-high potency TCS/TCI

+ Basic treatment ● Immunosuppressants: The majority of systemic therapies are not FDA

antihistamines approved and are also not recommended for moderate Low-mid potency TCS and/or TCI + Basic treatment long term use due to potential, serious immunosuppressing side effects(4)

mild Emollients, skin hydration ● Phototherapy (UV): Inconvenient and not available for all patients(5)

Antibiotic therapy used on frequent basis with recurrent infections (most Staphylococcus aureus)

TCS: Topical Corticosteroids; TCI: Topical Calcineurin inhibitors Systemic therapy include oral corticosteroids and immunosuppressants (mostly used off-label, with the exception of cyclosporine, which is licensed for short-term treatment of severe refractory AD in European countries). (1) Akdis CA et al. Allergy. 2006;61:969-987 (2) Guidelines by the Practical Consensus Group EAACI+AAAAI. Japanese guidelines relatively similar (3) Eichenfield LF at al. J Am Dermatol. 2014;71:116-132 (4) Akhavan A et al. Semin Cutan Med Surg. 2008;27:151-155 (5) Grundmann SA et al, J Allergy (Cairo). 2012;2012:121797 22 ® U.S. Launch Planning Focused on Patients with the Highest Unmet Medical Need

Physician Focus Patient Focus

Target physicians who Moderate to severe AD treat AD patients and patients intolerant to or who have experience inadequate response prescribing biologics to an existing therapy (i.e. Psoriasis) (e.g. Topicals, Oral/systemic steroids, Up to 7,000 doctors Immuno-suppressants) in the U.S. Around 300,000 adult patients in the U.S.

Dupixent® is developed in collaboration with Regeneron Pharmaceuticals, Inc. ® Dupixent is an investigational agent under clinical development and its safety and efficacy has not been fully evaluated by any Regulatory Authority 23 Moderate-to-Severe Asthma Negatively Impacts the Lives of Patients and Is Associated with High Burden to Society

● 235-300m people worldwide estimated to be affected by asthma(1) ● Chronic inflammatory disease leading to acute and chronic narrowing of the airway and increased mucus production ● Patients with asthma experience wheezing, shortness of breath, cough and chest tightness.

A second pivotal dupilumab study in adults with uncontrolled moderate-to-severe asthma is ongoing(2)

(1) WHO, http://www.who.int/mediacentre/factsheets/fs307/en/ (2) Based on discussions with the U.S. FDA, the Phase 2b study may be considered one of two pivotal efficacy studies required for a potential dupilumab biologics license application (BLA) in asthma. The Phase 3 clinical trial of dupilumab in patients with uncontrolled moderate-to-severe asthma, known as LIBERTY ASTHMA QUEST, will serve as the second required pivotal efficacy study. 2424 64-75% Reduction in Exacerbations in Phase 2b in Moderate-to-Severe Asthma

Annualized Rate of Severe Exacerbation Events(1)

1.2

1.0

0.8

-71%* ‡ † -70% † -68% Placebo 0.6 -81% -71%‡ -60%* 200mg Q2W 0.4 300mg Q2W

0.2

0.0 High Eosinophils Low Eosinophils Overall population Population Population * p<0.05 vs placebo † p<0.01 vs placebo ‡ p<0.001 vs placebo

Dupilumab is developed in collaboration with Regeneron Pharmaceuticals, Inc. (1) Adjusted annualized severe exacerbation rates were derived from the 24-week treatment period During the treatment period, patients continue their stable medium- or high-dose inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination product Wenzel S et al. Lancet. April 26, 2016 http://dx.doi.org/10.1016/ S0140-6736(16)30307-5 25 Improvement in Lung Function in Phase IIb in Moderate-to-Severe Asthma

Phase IIb - Mean Improvement in FEV1 at 24 Weeks (mL and % Change from Baseline) mL

400 22.9%* 24.9%†

‡ 300 16.6% 17.3%‡

† † 12.8% 13.4% 12.6% 200 Placebo 200mg Q2W 7.0% 300mg Q2W 100 4.7%

0 High Eosinophils Low Eosinophils Overall population Population Population * p<0.05 vs placebo † p<0.01 vs placebo ‡ p<0.001 vs placebo Dupilumab is developed in collaboration with Regeneron Pharmaceuticals, Inc. FEV1=forced expiratory volume over one second During the treatment period, patients continue their stable medium- or high-dose inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination product 26 Wenzel S et al. Lancet. April 26, 2016 http://dx.doi.org/10.1016/ S0140-6736(16)30307-5 Safety Profile in Moderate-to-Severe Asthma

Phase IIb Study Injection site Severe AEs Infections reactions 59.2% 53.2% 52.0%

Range in 26.9% dupilumab dose 13.3% cohorts 12.7% 10.2% 5.7% 4.0%

Dupilumab Placebo Dupilumab Placebo Dupilumab Placebo

● Injection site reaction was the most common TEAE and more frequent with dupilumab ● Incidence of infections and Severe TEAEs was balanced across treatment groups ● Other common adverse events in the study included upper respiratory tract infection, headache, nasopharyngitis and bronchitis

Dupilumab is developed in collaboration with Regeneron Pharmaceuticals, Inc. Final 24wk safety results from all dupilumab dose cohorts in the Phase 2b study 27 Wenzel S et al. Lancet. April 26, 2016 http://dx.doi.org/10.1016/ S0140-6736(16)30307-5 Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

28 Re-Building a Competitive Position in Oncology

● Product profile potentially differentiated ● Targets unique epitope with a distinct combination MoA(1) Isatuximab (2) (anti-CD38) ● Phase 3 study in relapsed/refractory multiple myeloma initiated in December ● Potential indications beyond multiple myeloma being explored

● Pivotal Phase 2/3 study in cutaneous squamous cell carcinoma ongoing PD-1 ● Phase 2 study in basal cell carcinoma expected to start in H1 2017 (REGN2810) ● Start of Phase 2 study in non-small cell lung cancer planned for H1 2017

Sanofi’s Antibody Drug Conjugates (ADCs) in Phase 1 complementary to our multi-specific antibody platform and IO strategy

MoA: Mechanism of Action (1) HDeckert, et al. Clin Cancer Res 2014;20:4574–83. (2) ICARIA-MM: A phase 3 randomized, open-label, multicenter study comparing Isatuximab (SAR650984) in Combination with Pomalidomide And Low- 29 Dose Dexamethasone verRsus Pomalidomide and Low-Dose Dexamethasone In patients with refractory or relapsed and refractory Multiple Myeloma 2017 Will Be a Busy Year for Sanofi Genzyme

Expected Regulatory Decisions Q1 Q2 Q3 Q4 ● Dupixent®(1) in Atopic Dermatitis (U.S.)  ● Kevzara® in Rheumatoid Arthritis (U.S.)  ● Kevzara® in Rheumatoid Arthritis (EU) Expected Regulatory Submissions Q1 Q2 Q3 Q4 ● Kevzara® in Rheumatoid Arthritis (U.S.)  ● Dupixent®(1) in Atopic Dermatitis (Japan)  ● dupilumab in Asthma in Adult patients (U.S.)  Expected Phase III / IIIb Topline Data Q1 Q2 Q3 Q4 ● patisiran in Familial amyloidotic polyneuropathy  ● dupilumab in Asthma in Adult patients  Expected Phase III Starts Q1 Q2 Q3 Q4 ● dupilumab in Asthma in patients aged 6-11 year-old  ● fitusiran (ALN-AT3) in Hemophilia  ● Dupixent®(1) AD in 6-11 and 12-17 year-old

(1) The European Medicines Agency (EMA) and FDA have conditionally accepted Dupixent® as the trade name for dupilumab. 30